Germany Female Health Technology “FemTech”
Executive Summary
Germany’s healthcare system is experiencing growing momentum in female-focused health technologies, commonly known as FemTech. This sector includes digital products and services addressing female specific health interventions such as fertility technologies, menstrual health, pregnancy and postpartum care, and other diagnostics related to female health. Its growth is driven by demographic shifts, increasing demand for personalized healthcare, and regulatory reforms in the region that enable the integration of digital health solutions into the country’s healthcare framework such as the Digital Health Care Act.
Market Overview
The German FemTech market generated a revenue of USD 1,319.4 million in 2023 and is projected to grow substantially, reaching USD 3.73 billion by 2030. This corresponds to a robust annual growth rate (CAGR) of approximately 16% during the 2024-2030 period. Germany’s FemTech market is positioned for sustainable growth through 2030, driven by both consumer demand and healthcare modernization.
Market Segmentation
Market segmentation in the FemTech industry is comprised of devices, software, services, and consumer products. Devices accounted for 33.4% of revenue in 2024, making the device segment both the largest and one of the fastest growing categories in the German market.
Reproductive health solutions, including fertility and contraceptive tools, are leading health related segments in the German FemTech market. This segmentation is consistent with global trends where reproductive health accounts for approximately 35% of digital health applications worldwide.
In Germany, emerging segments such as mental wellness, menopause, and midlife health are gaining traction, driven by advances in artificial intelligence (AI), wearables like pelvic floor trainers, and digital health apps integrated into the public healthcare system.
Competitive Landscape
Germany’s FemTech sector is rapidly evolving with increased competition among startups and international firms. Berlin serves as the main innovation hub, hosting leading companies like Clue, a global menstrual and fertility tracking app with over 12 million users, and Inne, which offers a clinically backed, saliva-based hormone monitoring device for fertility tracking. Venture capital investment in German FemTech is rising, positioning Germany among the top EU countries for FemTech funding.
Challenges
Regulatory factors such as the Digital Health Applications (DiGA) framework provide reimbursement opportunities for confirmed products and services, but many FemTech solutions remain consumer-paid resulting in limitations for broader adoption. Additionally, complex regulations, strict data privacy laws (GDPR), and cultural sensitivities present challenges, especially for non-EU competitors. The market favors companies that effectively combine clinical endorsement with regulatory compliance.
Opportunities
Innovation in artificial intelligence and big data technologies present significant potential for delivering personalized, data-driven health solutions that align with patient preferences. Evolving reimbursement policies under Germany’s DiGA framework are expected to expand FemTech adoption by improving affordability and integration into public healthcare. The country’s aging female demographic further drives demand for innovative menopause and midlife health solutions. Growing venture capital interest and strategic partnerships between startups and established firms accelerate market growth and innovation.
Trade Shows
DMEA Digital Health Trade Show - Berlin
Medica Medical Technology Trade Show - Dusseldorf
U.S. Department of Commerce, International Trade Administration, Contact Information:
For additional Information, please contact:
Ulrike Riegeler
Commercial Specialist
Email: Ulrike.Riegeler@trade.gov
Phone: +49 69 7535 3157